Podcast
Hybrid Synthesis is Redefining Peptide Manufacturing
“Drug candidates that previously would not have been considered feasible — they’re now on the table. Hybrid synthesis is opening the door to peptide drugs you’re going to need in larger quantities.” Brian Gregg, CEO of AmbioPharm, has spent his
9 March 2020